# Surface Oncology (stock symbol: SURF) Logo in transparent PNG and SVG formats

## Surface Oncology Logo large

### Surface Oncology Logo large Download PNG (79.87 KB)

![Surface Oncology Logo large Download PNG (79.87 KB)](/img/orig/SURF_BIG-8b9f7e9e.png)

### Surface Oncology Logo large Download SVG (13.13 KB)

![Surface Oncology Logo large Download SVG (13.13 KB)](/img/orig/SURF_BIG-c5968c9d.svg)

## Surface Oncology Logo icon format

### Surface Oncology Logo icon format Download PNG (45.25 KB)

![Surface Oncology Logo icon format Download PNG (45.25 KB)](/img/orig/SURF-1990a84c.png)

### Surface Oncology Logo icon format Download SVG (1.51 KB)

![Surface Oncology Logo icon format Download SVG (1.51 KB)](/img/orig/SURF-a17c96b5.svg)

## Surface Oncology Logo large for dark backgrounds

### Surface Oncology Logo large for dark backgrounds Download PNG (79.31 KB)

![Surface Oncology Logo large for dark backgrounds Download PNG (79.31 KB)](/img/orig/SURF_BIG.D-1480a58c.png)

### Surface Oncology Logo large for dark backgrounds Download SVG (12.33 KB)

![Surface Oncology Logo large for dark backgrounds Download SVG (12.33 KB)](/img/orig/SURF_BIG.D-150445ac.svg)

## Surface Oncology Logo icon format for dark backgrounds

### Surface Oncology Logo icon format for dark backgrounds Download PNG (44.02 KB)

![Surface Oncology Logo icon format for dark backgrounds Download PNG (44.02 KB)](/img/orig/SURF.D-59947c6b.png)

### Surface Oncology Logo icon format for dark backgrounds Download SVG (1.51 KB)

![Surface Oncology Logo icon format for dark backgrounds Download SVG (1.51 KB)](/img/orig/SURF.D-1fb679e8.svg)

## About Surface Oncology

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

1. Website domain: surfaceoncology.com
2. Employees: 67
3. Marketcap: $34.91 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
